Chat with us in Facebook Messenger. Find out what's happening in the world as it unfolds.

    JUST WATCHED

    Novartis, GlaxoSmithKline ink $20B deal

MUST WATCH

Novartis, GlaxoSmithKline ink $20B deal

Jim Boulden speaks to the CEO's of GSK and Novartis about why they've agreed to swap assets and combine business units.

Novartis, GlaxoSmithKline ink $20B deal

Jim Boulden speaks to the CEO's of GSK and Novartis about why they've agreed to swap assets and combine business units.